Seraph Biosciences

Executive Summary

Seraph Biosciences is a Detroit-based diagnostics company developing rapid pathogen detection systems that combine spectroscopy and artificial intelligence. Founded in 2016, the company aims to provide faster, on-site diagnostic solutions for healthcare and food safety applications. By leveraging its proprietary AI-powered spectral analysis platform, Seraph enables real-time identification of pathogens without the need for traditional culture methods, significantly reducing turnaround times from days to minutes. This technology addresses critical needs in infection control, antibiotic stewardship, and food contamination prevention. Despite being in a competitive landscape, Seraph's approach offers potential advantages in speed, accuracy, and ease of use. The company has yet to disclose funding or commercialization milestones, but its product development progress and potential partnerships could drive near-term growth. With increasing demand for rapid diagnostics post-pandemic, Seraph is well-positioned to capture market share if it executes its technology roadmap effectively.

Upcoming Catalysts (preview)

• Q4 2026Launch of first commercial pathogen detection system40% success
• Q3 2026Strategic partnership with a major food safety or healthcare company50% success
• Q2 2026Publication of validation study in a peer-reviewed journal60% success